Cytisine to Quit Smoking: Does This Plant Pill Work?

The internet has been whispering about a cheap "plant pill" that Eastern Europe has used to quit smoking for half a century, while the US still has only varenicline and bupropion plus the patch. Some of that whisper is true. Cytisine is a real medicine with real trials. Some of it is a trap: it is not a detox tea, it is not FDA-approved in the United States as of August 2026, and ordering a tin of Tabex from a random site is not how you get the trial results. Here is what the drug actually is, what the evidence says, why the US is late, and who it is for.

What Is Cytisine (and Why Is It Also Called Cytisinicline)?

Cytisine is an alkaloid originally extracted from the seeds of Laburnum anagyroides, the golden-chain or laburnum tree. The raw plant is toxic. The tablet is a purified, dose-controlled drug. Calling it "plant-based" is botanically accurate and commercially misleading if you hear "natural and therefore gentle." It is a nicotine-receptor medicine, in the same family as varenicline.

The naming mess is bureaucratic, not chemical:

• Cytisine is the older name, still what most people search. Brands such as Tabex (Sopharma, Bulgaria) and Desmoxan have used the 1.5 mg, 25-day pack in Eastern Europe since the 1960s.
• Cytisinicline is the International Nonproprietary Name the WHO now prefers. The UK renamed its licensed 1.5 mg tablets to cytisinicline in 2025. In the US, Achieve Life Sciences is developing a different tablet (3 mg, three times a day for 6 or 12 weeks) under that name.

Same molecule, two products, two schedules. Mix them up and the trial numbers stop matching the blister pack in your hand.

How It Works

Nicotine locks onto nicotinic acetylcholine receptors in the brain, especially the α4β2 subtype, and dumps dopamine. That is the relief, the focus, and the reason a bad day still ends with a cigarette. Cytisine is a partial agonist at those same receptors. It turns them on enough to take the edge off withdrawal, and it occupies them so that a real cigarette cannot deliver a full hit. The first week often feels strangely muted: you can smoke, and it is less interesting, which is the point.

It contains no nicotine. That is the feature people like, and also why you should not treat it as a patch you can layer with a leftover vape. UK product information warns that combining it with smoking or other nicotine products can intensify nicotine-like side effects. The licensed 25-day course tells you to stop smoking no later than day 5.

Does It Actually Work?

Short answer: yes, better than placebo, usually better than NRT, and in the same neighborhood as varenicline depending on the course you use.

Against placebo. A Cochrane review of nicotine-receptor partial agonists found cytisine helps more people quit than placebo (moderate-certainty evidence). A 2024 meta-analysis of eight placebo-controlled trials put the effect at more than a twofold increase in quit rates, with a number needed to treat around 11. Intensity of behavioral support tracks with how well it works, which is the same pattern as every other cessation drug.

Against NRT. The landmark comparison is Walker and colleagues in the New England Journal of Medicine (2014): 1,310 New Zealand smokers randomized to cytisine or nicotine replacement. At one month, continuous abstinence was 40 percent on cytisine versus 31 percent on NRT. The cytisine group was still ahead at six months. NICE's February 2025 update of guideline NG209 reached the same directional conclusion: cytisine was more effective than placebo or NRT in the evidence the committee reviewed.

Against varenicline (Chantix). This is the honest asterisk. Courtney and colleagues (JAMA, 2021) randomized 1,452 Australian smokers to the standard 25-day cytisine pack or 12 weeks of varenicline. Verified six-month abstinence was 11.7 percent versus 13.3 percent. That small gap meant the trial failed its non-inferiority test: they could not claim the short cytisine course was as good as the long varenicline course. Cytisine did cause fewer side effects. Cochrane's pooled cytisine-versus-varenicline comparison found no clear difference (low-certainty evidence). UK NICE guidance now lists cytisinicline, varenicline, and combination NRT as the preferred, most effective options.

The US trials use a different recipe. ORCA-2 (JAMA, 2023) tested cytisinicline 3 mg three times daily for 6 or 12 weeks in 810 US adults. End-of-treatment continuous abstinence was 25.3 percent versus 4.4 percent placebo after six weeks, and 32.6 percent versus 7.0 percent after twelve weeks. Through 24 weeks, the 12-week arm held 21.1 percent versus 4.8 percent. ORCA-3, a replication in 792 people, again beat placebo on both schedules, with the 12-week arm at 30.3 percent versus 9.4 percent at the end of treatment. Nausea, abnormal dreams, and insomnia stayed under 10 percent in ORCA-2, and 2.9 percent of people discontinued for an adverse event.

So: the molecule works. The 25-day European pack is not automatically "as good as Chantix." The longer 3 mg US schedule looks strong against placebo and has not yet had a published head-to-head against varenicline.

The Two Courses, Because They Are Not Interchangeable

| | Licensed UK / Eastern European pack | US trial (cytisinicline) | |---|---|---| | Tablet | 1.5 mg | 3 mg | | How often | Taper from 6 per day down to 1-2 over 25 days | 3 times daily, no taper during the course | | Length | 25 days | 6 or 12 weeks | | Quit timing | Stop smoking by day 5 | Behavioral support throughout; abstinence measured in the last 4 weeks of drug | | Who it is licensed for | Typically ages 18-65 in UK labeling | Trial adults; not FDA-approved |

The UK 25-day schedule, from NICE CKS, runs:

• Days 1-3: 1 tablet every 2 hours (max 6/day)
• Days 4-12: every 2.5 hours (max 5)
• Days 13-16: every 3 hours (max 4)
• Days 17-20: every 5 hours (max 3)
• Days 21-25: 1 to 2 tablets a day

Miss the taper and you are not taking the medicine that was studied. The US 3 mg three-times-daily design exists partly because that 6-times-a-day European pack is hard to follow.

Is Cytisine Available in the US?

No. As of 30 August 2026 there is no FDA-approved cytisine or cytisinicline product for smoking cessation in the United States.

Achieve Life Sciences submitted an NDA in 2025. On 22 June 2026 the FDA issued a Complete Response Letter. The letter cited outstanding cGMP observations from an inspection of a third-party manufacturing facility and final product labeling that was not completed by the action date. Achieve and subsequent reporting were explicit: the FDA did not identify deficiencies in clinical efficacy or safety. That distinction matters. This is not "the trials failed." It is "the factory paperwork and the label were not done."

The company says it has moved commercial manufacturing to US-based Adare Pharma Solutions, plans to resubmit in the fourth quarter of 2026, and has discussed a possible approval in the first half of 2027. Treat those dates as the company's timeline, not a promise from the FDA.

What about Tabex from the internet? It is the original Bulgarian brand, and in countries where it is regulated it is a real drug. Shipped into the US as an unapproved import, it is a gamble on identity, dose, and contaminants. It also will not match the ORCA schedule even if the tablet is genuine. Wait for a licensed product, or use the tools that are already legal: combination nicotine replacement, varenicline, or bupropion.

Outside the US the picture is different. The UK MHRA licensed cytisine in 2019; it reached the market in 2024, NICE added it to NG209 in February 2025, and NHS stop-smoking pathways can prescribe it. Other European countries have sold Tabex or equivalents for decades. If you are reading this in a licensed country, the question is not "does this exist" but "is it the right option for me," which is a clinician conversation.

Side Effects, Who Should Skip It, and the Fine Print

Common effects in trials and UK labeling: nausea, sleep changes and vivid dreams, headache, dry mouth, digestive upset, dizziness, fatigue, appetite or weight change, and a faster heart rate. Many of those also happen in untreated withdrawal, which is why people misread them. They are usually mild. The ORCA program's discontinuation rate for adverse events was low, and no drug-related serious events were identified in ORCA-2.

UK labeling is stricter than a US trial protocol. Do not use the licensed 1.5 mg product if you are under 18, 66 or older, pregnant, or breastfeeding, or if you have unstable angina, a recent heart attack, significant arrhythmia, a recent stroke, or renal or hepatic impairment. Cautions include other cardiovascular disease, ulcers or reflux, diabetes, thyroid disease, and a history of psychiatric illness. It should not be combined with anti-tuberculosis medicines. NICE and the BNF also advise against combining it with NRT, varenicline, or bupropion.

Hormonal contraception. The UK SmPC and BNF say it is unknown whether cytisinicline reduces the effectiveness of combined hormonal contraceptives. The advice is theoretical, not a proven failure rate: use a barrier method as well while you are on the course. That is caution, not a moral panic.

Pregnancy. Avoid it. Limited data, and UK guidance is explicit. If you are pregnant and still smoking, the evidence-based path is counseling plus, where a clinician agrees, NRT. That plan lives in our pregnancy quitting guide, not in a cytisine blister pack.

Can It Help With Vaping?

The mechanism does not care whether the nicotine arrived in smoke or vapor. In July 2024 the FDA granted cytisinicline Breakthrough Therapy designation for nicotine e-cigarette cessation, which is a development fast-track, not an approval. There is currently no FDA-approved medicine specifically for quitting vapes. Encouraging trial signals exist; licensed UK packs are still a smoking-cessation indication. If vaping is what you need to stop, build the quit around a vaping-specific plan and proven NRT rather than waiting on a designation.

How to Use It If You Can Get It

If you live where cytisinicline is licensed, treat it like the other proven pills, not like a supplement:

1. Get it through a clinician or stop-smoking service, not a marketplace listing. They will check the heart, kidney, pregnancy, and drug-interaction list.
2. Set a quit date that matches the pack. On the 25-day course that means cigarettes are gone by day 5, not "I'll see how I feel."
3. Follow the taper or the three-times-daily clock exactly. This is a schedule drug. Missed midday tablets are how people decide "it did nothing."
4. Pair it with behavioral support. Every guideline says the same thing: the tablet blunts the chemistry, it does not retire the coffee-and-cigarette script. A written step-by-step quit plan plus a visible streak (smoke-free days, money saved, cravings logged) is the other half. That is what Smoke Tracker is for: making the course you are on visible after the novelty of a new blister pack wears off.
5. Have a 90-second plan for spikes. A pill taken at breakfast cannot react to a 4 p.m. argument. Slow breathing at about six breaths a minute is the fastest non-drug reset, and a short session in a companion app like Flow Breath is easier to start than "remember to breathe" while your hands look for a pack.
6. If this course fails, wait. UK labeling says you can try again after two to three months rather than immediately restacking tablets.

If you are in the US, the useful move is not a countdown to 2027. It is starting a legal, evidence-based attempt now with combination NRT or a prescription your clinician can actually fill.

The Bottom Line

Cytisine is not a rumor and it is not a miracle. It is a decades-old nicotine-receptor pill that helps people quit, usually with fewer side effects than varenicline, in a short 25-day European pack or a longer 3 mg US trial schedule. The UK has already put it on the same shelf as Chantix and combination NRT. The US has not, because of manufacturing and labeling, not because the trials collapsed. Until there is an FDA-approved tablet, Americans should use the approved tools and ignore the "buy Tabex" threads. Where the drug is licensed, it is a strong option for someone who wants a nicotine-free tablet, can follow a fussy schedule, and will still do the behavioral work the blister pack cannot do.

This article is for general educational purposes and is not medical advice. Cytisine/cytisinicline is a prescription medicine in licensed markets, with real contraindications (including pregnancy, certain heart conditions, and age limits on some packs). Always consult a qualified clinician before starting, stopping, or combining any quit-smoking medication. US availability described here reflects publicly reported FDA and company status as of August 2026 and can change.

Sources

1. Walker N, et al. "Cytisine versus Nicotine for Smoking Cessation." New England Journal of Medicine, 2014. nejm.org
2. Courtney RJ, et al. "Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial." JAMA, 2021. pubmed.ncbi.nlm.nih.gov
3. Rigotti NA, et al. "Cytisinicline for Smoking Cessation: A Randomized Clinical Trial" (ORCA-2). JAMA, 2023. pubmed.ncbi.nlm.nih.gov
4. Rigotti NA, et al. "Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial" (ORCA-3). JAMA Internal Medicine, 2025. pubmed.ncbi.nlm.nih.gov
5. Livingstone-Banks J, et al. "Nicotine receptor partial agonists for smoking cessation." Cochrane Database of Systematic Reviews, 2023. cochrane.org
6. NICE guideline NG209. "Tobacco: preventing uptake, promoting quitting and treating dependence." Updated February 2025. nice.org.uk
7. NICE CKS. "Cytisinicline: prescribing information." cks.nice.org.uk
8. BNF. "Cytisinicline." bnf.nice.org.uk
9. Achieve Life Sciences. Complete Response Letter announcement, 22 June 2026. Reported by Reuters and company release: manufacturing and labeling, no clinical efficacy or safety deficiencies; resubmission planned Q4 2026.
10. U.S. FDA Breakthrough Therapy designation for cytisinicline in nicotine e-cigarette cessation, July 2024 (Achieve Life Sciences announcement).
11. NHS Better Health. "Quit smoking with nicotine-free medicines." nhs.uk
12. De Santi O, et al. "Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis." Addiction, 2024. pubmed.ncbi.nlm.nih.gov